A Phase II/III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Relaxin in Subjects With Acute Heart Failure
Latest Information Update: 12 Aug 2022
At a glance
- Drugs Serelaxin (Primary)
- Indications Acute heart failure
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms Pre-RELAX-AHF; RELAX; RELAX-AHF
- Sponsors Corthera; Novartis Pharma
- 03 Aug 2022 Results assessing the role of NLR in predicting cardiovascular outcomes in patients with acute heart failure from BLAST-AHF, Pre-RELAX-AHF & RELAX-AHF, published in the American Journal of Cardiology.
- 01 Apr 2022 Results of a retrospective patient level analysis from 4 randomized controlled trials (NCT02064868, NCT02007720, NCT01870778, NCT00520806) assessing serelaxin in acute heart failure published in the Circulation: Heart Failure
- 17 Nov 2020 Results assessing real-world cohort of hemodynamically-proven HFpEF few patients will met criteria for enrollment in major HFpEF clinical trials (TOPCAT, I-PRESERVE, PARAGON-HF, and RELAX), presented at the American Heart Association Scientific Sessions 2020.